Niowave is a domestic supplier of medical and industrial radioisotopes from uranium fission and stable targets. Isotope inventories available for purchase include alpha, beta, and gamma sources. The system uses a superconducting linac instead of a nuclear reactor which is simpler to operate and less costly to license. It also eliminates the need for a nuclear reactor and weapons grade uranium (HEU). The small batch radiochemistry operations can be automated, and do not require licensing as a nuclear reprocessing facility. Isotope production and distribution utilize existing radiopharmaceutical supply chain and FDA approval processes.
$500K sweet spot round size
2005
$500K
from 1 investors over 1 rounds
Niowave, Inc. raised $500K on May 11, 2023
Investors: Michigan Economic Development Corporation